- Built six independently trained per-modality models (bulk RNA-seq, DNA methylation, miRNA, copy-number, somatic-mutation, and a leakage-safe clinical model) by porting the Cedars-Sinai / Betteromics Molecular-Twin methodology to the TCGA head-and-neck cohort, evaluated over 1,206 samples from 1,160 patients (58,147 genes) under patient-grouped, label-stratified 5-fold cross-validation with zero leaked patients.
- Reframed the task from binary oral-vs-rest detection to ten-class tumour typing, reaching 0.84 accuracy and 0.90 balanced accuracy while confining almost all error to the clinically hard oral vs non-oral head-and-neck block that the binary framing had masked.
- Engineered a deployed decision-support system in which a self-hosted Qwen3-32B orchestrator aggregates the six model predictions weighted by cross-validated reliability, backed by a knowledge-graph RAG fallback on low confidence and a deterministic safety layer that only escalates risk.
- Diagnosed a training-set leakage confound (weak modalities scoring a perfect 1.000 against honest ROC-AUCs of 0.60 to 0.82) that capped both the LLM and ML baselines at a ~0.98 ceiling, and specified the held-out-cohort correction required for a valid comparison.